177 related articles for article (PubMed ID: 32064343)
1. Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of
Karaayvaz-Yildirim M; Silberman RE; Langenbucher A; Saladi SV; Ross KN; Zarcaro E; Desmond A; Yildirim M; Vivekanandan V; Ravichandran H; Mylavagnanam R; Specht MC; Ramaswamy S; Lawrence M; Amon A; Ellisen LW
Sci Adv; 2020 Jan; 6(5):eaay2611. PubMed ID: 32064343
[TBL] [Abstract][Full Text] [Related]
2. Heterozygous mutations in PALB2 cause DNA replication and damage response defects.
Nikkilä J; Parplys AC; Pylkäs K; Bose M; Huo Y; Borgmann K; Rapakko K; Nieminen P; Xia B; Pospiech H; Winqvist R
Nat Commun; 2013; 4():2578. PubMed ID: 24153426
[TBL] [Abstract][Full Text] [Related]
3. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
Adamson AW; Ding YC; Mendez-Dorantes C; Bailis AM; Stark JM; Neuhausen SL
Mol Oncol; 2020 Jun; 14(6):1124-1133. PubMed ID: 32175645
[TBL] [Abstract][Full Text] [Related]
4.
Gunnarsdottir SR; Bjarnason H; Thorvaldsdottir B; Paland F; Steinarsdottir M; Eyfjörd JE; Bödvarsdottir SK
Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052422
[TBL] [Abstract][Full Text] [Related]
5. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
6. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
7. High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
Castro E; Jugurnauth-Little S; Karlsson Q; Al-Shahrour F; Piñeiro-Yañez E; Van de Poll F; Leongamornlert D; Dadaev T; Govindasami K; Guy M; Eeles R; Kote-Jarai Z;
Ann Oncol; 2015 Nov; 26(11):2293-300. PubMed ID: 26347108
[TBL] [Abstract][Full Text] [Related]
8. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
[TBL] [Abstract][Full Text] [Related]
9. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL
BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers.
Stevens KN; Wang X; Fredericksen Z; Pankratz VS; Greene MH; Andrulis IL; Thomassen M; Caligo M; ; Nathanson KL; Jakubowska A; Osorio A; Hamann U; Godwin AK; Stoppa-Lyonnet D; Southey M; Buys SS; Singer CF; Hansen TV; Arason A; Offit K; Piedmonte M; Montagna M; Imyanitov E; Tihomirova L; Sucheston L; Beattie M; ; ; Neuhausen SL; ; Szabo CI; ; Simard J; Spurdle AB; Healey S; Chen X; Rebbeck TR; Easton DF; Chenevix-Trench G; Antoniou AC; Couch FJ
Breast Cancer Res Treat; 2012 Nov; 136(1):295-302. PubMed ID: 23011509
[TBL] [Abstract][Full Text] [Related]
11. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study.
West AH; Knollman H; Dugan J; Hedeker D; Handorf EA; Nielsen SM; Bealin LC; Goldblatt LG; Willems H; Daly MB; Afghahi A; Olopade OI; Hulick PJ; Shagisultanova E; Huo D; Obeid E; Churpek JE
Cancer Med; 2019 Sep; 8(12):5609-5618. PubMed ID: 31407530
[TBL] [Abstract][Full Text] [Related]
12. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
13. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers.
Huo Z; Giger ML; Olopade OI; Wolverton DE; Weber BL; Metz CE; Zhong W; Cummings SA
Radiology; 2002 Nov; 225(2):519-26. PubMed ID: 12409590
[TBL] [Abstract][Full Text] [Related]
14. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?
Semple J; Metcalfe KA; Lubinski J; Huzarski T; Gronwald J; Armel S; Lynch HT; Karlan B; Foulkes W; Singer CF; Neuhausen SL; Eng C; Iqbal J; Narod SA;
Breast Cancer Res Treat; 2015 Nov; 154(1):163-9. PubMed ID: 26467043
[TBL] [Abstract][Full Text] [Related]
15. Lower level of BRCA2 protein in heterozygous mutation carriers is correlated with an increase in DNA double strand breaks and an impaired DSB repair.
Arnold K; Kim MK; Frerk K; Edler L; Savelyeva L; Schmezer P; Wiedemeyer R
Cancer Lett; 2006 Nov; 243(1):90-100. PubMed ID: 16448746
[TBL] [Abstract][Full Text] [Related]
16. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.
Barwell J; Pangon L; Georgiou A; Kesterton I; Langman C; Arden-Jones A; Bancroft E; Salmon A; Locke I; Kote-Jarai Z; Morris JR; Solomon E; Berg J; Docherty Z; Camplejohn R; Eeles R; Hodgson SV
Int J Cancer; 2007 Oct; 121(7):1631-6. PubMed ID: 17582599
[TBL] [Abstract][Full Text] [Related]
18. Increased rates of spontaneous sister chromatid exchange in lymphocytes of BRCA2+/- carriers of familial breast cancer clusters.
Kim MK; Zitzmann S; Westermann F; Arnold K; Brouwers S; Schwab M; Savelyeva L
Cancer Lett; 2004 Jul; 210(1):85-94. PubMed ID: 15172125
[TBL] [Abstract][Full Text] [Related]
19. Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study.
Douvdevani A; Bernstein-Molho R; Asraf K; Doolman R; Laitman Y; Friedman E
Cancer Biomark; 2020; 28(3):269-273. PubMed ID: 32280079
[TBL] [Abstract][Full Text] [Related]
20. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.
Winter C; Nilsson MP; Olsson E; George AM; Chen Y; Kvist A; Törngren T; Vallon-Christersson J; Hegardt C; Häkkinen J; Jönsson G; Grabau D; Malmberg M; Kristoffersson U; Rehn M; Gruvberger-Saal SK; Larsson C; Borg Å; Loman N; Saal LH
Ann Oncol; 2016 Aug; 27(8):1532-8. PubMed ID: 27194814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
